As the world marks World Kidney Day, health experts are sounding the alarm about a critical and often overlooked medical threat: the powerful connection between kidney disease and heart health.
Medical professionals warn that people living with Chronic Kidney Disease face a significantly higher risk of developing serious cardiovascular complications, including Heart Failure, Stroke, Coronary Artery Disease, and Arrhythmia.
The growing concern highlights why early screening, awareness, and advanced treatments are becoming increasingly vital in protecting millions of people at risk.
The Hidden “Cardio-Renal-Metabolic” Connection
Health experts now describe the interaction between the heart, kidneys and metabolism as a “cardio-renal-metabolic system” — a delicate biological balance where dysfunction in one organ can trigger problems in the others.
This connection becomes even more complex when Type 2 Diabetes enters the picture, creating a dangerous trio of conditions that often occur together.
According to Ingrid Singels, Associate Director of the Scientific Division at Pharma Dynamics, these organs depend heavily on each other to maintain the body’s balance.
“The metabolic system is closely interlinked with the heart and kidneys, and these organs rely on one another to maintain the body’s balance,” she explains.
“The heart depends on the kidneys to regulate fluid balance, while the kidneys rely on the heart for proper blood flow.”
One of the biggest challenges with chronic kidney disease is that it often develops silently.
In many cases, patients experience no noticeable symptoms in the early stages, meaning kidney damage may already be significant by the time the condition is detected.
This makes education, screening and early intervention essential.
New Medical Breakthroughs Changing CKD Treatment
In recent years, medical research has delivered promising innovations that are transforming the way doctors treat kidney disease and related heart complications.
One example is Empagliflozin, part of a class of drugs known as SGLT2 inhibitors.
Originally developed to treat diabetes, these medicines have demonstrated remarkable benefits beyond blood sugar control.
Research shows that SGLT2 inhibitors can:
-
Protect kidney function
-
Reduce pressure in the kidneys
-
Improve metabolic health
-
Slow the progression of kidney disease
-
Lower the risk of heart failure and cardiovascular complications
Evidence also suggests that these treatments may delay the need for dialysis or kidney transplantation, helping patients maintain better quality of life for longer.
Importantly, their protective benefits appear to work across different stages of chronic kidney disease, even in people without diabetes.
Semaglutide Offers Multi-Organ Protection
Another major medical development is the expanded approval of Semaglutide, a therapy initially designed to manage type 2 diabetes.
New evidence from the landmark FLOW Trial, published in the New England Journal of Medicine in 2024, revealed powerful protective benefits.
The study found that semaglutide reduced serious kidney complications — including progression to end-stage kidney disease — by approximately 24% in patients living with chronic kidney disease and type 2 diabetes.
The treatment also significantly reduced the risk of major cardiovascular events and death, demonstrating its ability to protect both the kidneys and the heart simultaneously.
According to Singels, this represents a significant breakthrough in patient care.
“Semaglutide’s ability to protect both the kidneys and the heart represents a new frontier in patient care,” she says.
“These innovations highlight why personalised treatment that considers the whole patient is so important.”
Access to Treatment Remains a Challenge in South Africa
Despite these promising advances, access to the latest therapies remains a challenge for many South Africans.
While treatments such as empagliflozin and semaglutide are transforming the management of diabetes and chronic kidney disease globally, availability in South Africa is still largely concentrated in the private healthcare sector.
High out-of-pocket costs mean many uninsured and lower-income patients struggle to access these potentially life-saving medicines.
Singels believes that quality-assured generic medicines could play a crucial role in expanding treatment access.
As more affordable options become available, more patients may benefit from therapies proven to slow kidney disease progression and protect the heart.
Expanding access to clinically appropriate SGLT2 inhibitors and GLP-1 receptor agonists could significantly reduce South Africa’s growing burden of kidney and cardiovascular disease.
Questions Patients Should Ask Their Doctors
Health experts encourage South Africans — particularly those living with diabetes or high blood pressure — to take proactive steps by discussing the following questions with their healthcare providers:
-
Are my blood sugar, blood pressure and cholesterol levels well controlled?
-
What lifestyle changes could reduce my long-term health risks?
-
Do I have any risk factors for kidney disease?
-
Should my kidney function or urine protein levels be tested?
-
Would kidney- and heart-protective treatments such as SGLT2 inhibitors or GLP-1 receptor agonists be suitable for me?
A Global Call for Awareness and Early Detection
As World Kidney Day raises awareness around kidney health worldwide, Pharma Dynamics is joining global health organisations in calling for:
-
Greater public awareness campaigns
-
Expanded screening programmes
-
Increased investment in kidney research and treatment innovation
With early detection, improved access to life-saving therapies and a better understanding of the heart-kidney connection, health experts believe it is possible to change the trajectory of chronic kidney disease and cardiovascular complications — offering hope to millions at risk.
